Status:
TERMINATED
PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds
Lead Sponsor:
Government of Punjab, Specialized Healthcare and Medical Education Department
Collaborating Sponsors:
Mayo Hospital Lahore
Services Hospital, Lahore
Conditions:
Sars-CoV2
Symptomatic Condition
Eligibility:
All Genders
20-50 years
Phase:
PHASE4
Brief Summary
To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroq...
Eligibility Criteria
Inclusion
- Symptomatic patients: defined as fever (temperature greater than 100 degree F), cough, or shortness of breath (respiratory rate \>22 per minute).
- Nasopharyngeal RT-PCR positive SARS-CoV-2
- Age 20-50 years
- BMI 18-28 kg/m2
- Informed consent
Exclusion
- O2 saturation by pulse-oximeter below 93%
- Co-morbidities: any pre-existing cardiac disease, pulmonary disease, diabetes
- Arrhythmias and/or history of arrythmia
- Psoriasis and/or history of psoriasis
- Neuropathy or myopathy and/or history of these
- Hypoglycemia and/or history of hypoglycemia
- Pre-existing hepatic disease
- Pre-existing renal disease
- Use of antacids within 1 week
- Use of antiobiotics within 1 week
- Pregnancy
- RT-PCR performed \>7 days prior to enrollment
Key Trial Info
Start Date :
April 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2020
Estimated Enrollment :
137 Patients enrolled
Trial Details
Trial ID
NCT04351191
Start Date
April 15 2020
End Date
August 30 2020
Last Update
March 10 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Expo Covid Isolation Center / Mayo Hospital Field Hospital
Lahore, Punjab Province, Pakistan
2
Mayo Hospital / King Edward Medical University
Lahore, Punjab Province, Pakistan
3
Pakistan Kidney and Liver Institute
Lahore, Punjab Province, Pakistan
4
Services Hospital
Lahore, Punjab Province, Pakistan